Home > Publications database > Longitudinal associations of bioelectrical phase angle and fatigue in breast cancer patients. > print

001     276936
005     20240229155007.0
024 7 _ |a 10.1002/ijc.34630
|2 doi
024 7 _ |a pmid:37337948
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:151705538
|2 altmetric
037 _ _ |a DKFZ-2023-01213
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schmidt, Martina
|0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
|b 0
|e First author
|u dkfz
245 _ _ |a Longitudinal associations of bioelectrical phase angle and fatigue in breast cancer patients.
260 _ _ |a Bognor Regis
|c 2023
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1690462418_31842
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C110#LA:C110# / 2023 Sep 15;153(6):1192-1200
520 _ _ |a Cancer-related fatigue is commonly treated in an undifferentiated manner, because its pathophysiology is still not well understood. Therefore, we investigated if bioelectrical phase angle (PhA), a non-invasive marker of cell integrity, could help to single out specific fatigue subtypes. In a randomized controlled strength training intervention trial, PhA was measured by bioelectrical impedance analysis in 158 breast cancer patients. Fatigue was assessed with the multidimensional 20-item Fatigue Assessment Questionnaire. Multiple regression analyses considering changes in PhA and fatigue from baseline to post-intervention and ANCOVA models investigating the strength training effect on PhA were conducted. Further, explorative mediation and moderation analyses were performed. Decrease (=worsening) in PhA was significantly associated with increase in physical (P = .010) and emotional (P = .019) fatigue. These associations were markedly stronger in patients with normal BMI (interaction P = .059 and .097) and with low pre-diagnosis exercise level (interaction P = .058 and .19). Among patients with normal BMI strength training was associated with an increase in PhA (ANCOVA P = .059), but not among overweight/obese patients (interaction P = .035). Chemotherapy was a major determinant for low PhA, but PhA did not mediate the effect of chemotherapy on fatigue. In conclusion, PhA has a significant inverse association with physical and emotional fatigue. This association is moderated by BMI and previous exercise. Significant relationships of PhA were also observed with chemotherapy and strength training. Thus, PhA might be a marker that could help in the classification of subtypes of fatigue with different pathophysiology, which may require specifically tailored treatment. Further research on this is warranted.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a bioimpedance analysis
|2 Other
650 _ 7 |a cancer-related fatigue
|2 Other
650 _ 7 |a exercise
|2 Other
650 _ 7 |a quality of life
|2 Other
650 _ 7 |a survivorship
|2 Other
700 1 _ |a Chong, Marvin
|b 1
700 1 _ |a Klassen, Oliver
|b 2
700 1 _ |a Wiskemann, Joachim
|b 3
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1002/ijc.34630
|g p. ijc.34630
|0 PERI:(DE-600)1474822-8
|n 6
|p 1192-1200
|t International journal of cancer
|v 153
|y 2023
|x 0020-7136
909 C O |p VDB
|o oai:inrepo02.dkfz.de:276936
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2022-11-25
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
920 2 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 0 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21